Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Prism Research LLC

Neither a doctor nor a teaching hospital

Research payments

$17,654,853

695 payments

Through program year 2025, Prism Research LLC is reported as receiving $17,654,853 in research payments, across 695 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $919,869 30
2024 Research $737,984 179
2023 Research $1,683,120 53
2022 Research $2,555,355 100
2021 Research $5,685,131 176
2020 Research $3,909,567 107
2019 Research $2,163,827 50

Breakdown

Who paid Research payments · program years 2019–2025
  1. Sanofi US Services Inc. $6,754,005 115 payments
  2. Gilead Sciences, Inc. $3,520,501 99 payments
  3. Pfizer Inc. $1,636,331 99 payments
  4. Deciphera Pharmaceuticals Inc. $898,317 15 payments
  5. Eli Lilly and Company $885,845 8 payments
  6. Amgen Inc. $680,467 4 payments
  7. Genzyme Corporation $535,807 19 payments
  8. BioCryst Pharmaceuticals, Inc. $519,927 21 payments
  9. BioNTech SE $456,913 167 payments
  10. Otsuka Pharmaceutical Development & Commercialization, Inc. $421,863 6 payments
Studies the money was for Research payments · program years 2019–2025
  1. Tolerance Rep. Dose-Oral-Small molecules $1,412,305 11 payments
  2. Tolerance Single Dose- SC $1,273,017 14 payments
  3. Comparative Bioavailability $1,086,567 10 payments
  4. A Phase 1, Randomized, 2-Part Open-Label, Single Dose, Crossover Study to Evaluate the Relative Bioavailability and Safety of 2 Formulations of Rebastinib and the Effect of A High-Fat Meal on Rebastinib Pharmacokinetics in Healthy Adult Participants $889,735 13 payments
  5. Drug interaction - CYP3A4 Inhibitor $628,580 7 payments
  6. A Phase 1, Randomized, Double-blind, Placebo-controlled, Integrated Single Ascending Dose, Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AMG 691 in Healthy Participants and Participants With Mild-to-Moderate Asthma $586,069 2 payments
  7. Tolerance Single Dose-Oral-Small molecule $565,096 15 payments
  8. A Phase 1, Randomized, Sponsor-Unblinded, Placebo-Controlled Study to Evaluate the Effect of GS-4875 on Renal Function as Assessed by Markers of Glomerular Filtration Rate $465,022 1 payment
  9. Bnt331-01 $456,913 167 payments
  10. A Phase 1, Blinded, Randomized, Placebo Controlled, Multiple Dose Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Intravenous Remdesivir (GS 5734) $451,443 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record